Necrolytic Migratory Erythema: Case Report and Clinical Review

Journal of Cutaneous Medicine and Surgery

Volumn 7, Issue 4, 2003, Pages 333-338

  Adam, David N ^a,d,e   Cohen, Paul D ^b   Sibbald, R Gary ^b   Ghazarian, Danny ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; ERYTHEMA; FATALITY; HUMAN; MALE; METASTASIS; NECROLYTIC MIGRATORY ERYTHEMA; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REVIEW; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ERYTHEMA; GLUCAGONOMA; HUMANS; MALE; OCTREOTIDE; PANCREATIC NEOPLASMS; PARANEOPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 0242498627     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-002-0127-0     Document Type: Review

References (28)

1. Wilkinson DS. Necrolytic migratory erythema with carcinoma of the pancreas. Trans St. Johns Dermtol Soc 1973; 59:244-250.
2. Becker SW, Kahn D, Rothman S. Cutaneous manifestation of internal malignant tumors. Arch Dermatol Syphilol 1942; 45:1069-1080.
3. Wermers RA, Fatourechi V, Wynne AG, et al. The Glucagonoma Syndrome, clinical and pathologic features in 21 patients. Medicine 1996; 75:53-63.
4. Schwartz RA. Glucagonoma and pseudoglucagonoma syndromes. Int J Dermatol 1997; 36:81-89.
5. Chastain MA. The Glucagonoma Syndrome: A review of its features and discussion of new perspectives. Am J Med Sci 2001; 321(5):306-320.
6. Prinz RA, Dorsch TR, Lawrence AM. Clinical aspects of glucagon producing islet cell tumour. Am J Gastroenterol 1981; 76:125-131.
7. Lewis AE. The glucagonoma syndrome. Int J Dermatol 1979; 18:17-22.
8. Mozell E, Stenzel P, Woltering EA, et al. Functional endocrine tumors of the pancreas. Clinical presentation, diagnosis and treatment. Curr Probl Surg 1990; 27:310-386.
9. Stacpoole PW. The glucagonoma syndrome. Clinical features, diagnosis and treatment. Endocr Rev 1981; 2:347-361.
10. Sibrack LA, Gouterman IH. Cutaneous manifestation of pancreatic diseases. Cutis 1978; 21:763-768.
11. Dohlsten M, Hallberg T. Immunological studies in a patient with the glucagonoma syndrome. Acta Med Scand 1985; 218:251-255.
12. Wynick D, Hammond PJ, Bloom SR. The glucagonoma syndrome. Clin Dermatol 1993; 11:93-97.
13. Hunt SJ, Narus VT, Abell E. Necrolytic migratory erythema: dyskeratotic dermatitis, a clue to early diagnosis. J Am Acad Dermatol 1991; 24:473-477.
14. Kaplan EL, Michelassi F. Endocrine tumours of the pancreas and their clinical syndromes. Surg Annu 1986; 18:181-228.
15. Smith AP, Doolas A, Staren ED. Rapid resolution of necrolytic migratory erythema after glucagonoma resection. J Surg Oncol 1996; 61:306-309.
16. van der Loos TLJM, Lambrecht ER, Lambers JCCA. Successful treatment of glucagonoma-related necrolytic migratory erythema with dacarbazine. J Am Acad Dermatol 1987; 16:468-472.
17. Modlin IM, Lewis JJ, Ahlman H, et al. Management of unresectable malignant neuroendocrine tumors of the pancreas. Surg Gynecol Obstet 1993; 176:507-518.
18. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 316:519-523.
19. Makowka L, Tzakis AG, Mazzaferro V, et al. Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. Surg Gynecol Obstet 1989; 168:107-111.
20. Alsina AE, Bartus S, Hull D, et al. Liver transplantation for metastatic neuroendocrine tumor. J Clin Gastroenterol 1990; 12:533-537.
21. Sheppard ME, Raimer SS, Tyring SK, et al. Treatment of necrolytic migratory erythema in glucagonoma syndrome. J Am Acad Dermatol 1991; 25:925-928.
22. Jockenhovel F, Lederbogen S, Olbricht T, et al. The long acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of pre-pro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth. Clin Investig 1994; 72:127-133.
23. Siller GM, Strutton GM, Moore GA, et al. Glucagonoma syndrome with increased lactate dehydrogenase isoenzymes: Octreotide treatment. Australas J Dermatol 1994; 35:11-14.
24. Rosenbaum A, Flourie B, Chagnon S, et al. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature. Digestion 1989; 42:116-120.
25. Bewley AP, Ross JS, Bunker CB, et al. Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema. Br J Dermatol 1996; 134:1101-1104.
26. Blackford S, Wright S, Roberts DL. Necrolytic migratory erythema without glucagonoma: the role of dietary essential fatty acids. Br J Dermatol 1991; 125:460-462.
27. Burton JL. Zinc and essential fatty acid therapy for necrolytic migratory erythema. Arch Dermatol 1993; 129:246 [letter].
28. Delaney TJ, Uff JS. Necrolytic migratory erythema: apparent response to oral omega-3 (marine) essential fatty acids. Br J Dermatol 1990; 123(s37):107-109.